Tyra Biosciences, Inc. — Form 4
Filed September 17, 2026 · analyzed by the Insider Agent
4
▲ Likely positive
significance 78/100
What the filing says
Director RA CAPITAL MANAGEMENT, L.P. (TYRA) bought 9.1M shares (~$200.0M) on the open market (44% of holdings). Open-market insider purchase — historically a bullish signal.
Why this rating
Open-market insider purchase — historically a bullish signal.
Tradability signal
NO TRADE
No trade: positive news with only +1.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.27% over 4 hrs, n=94). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $24.43 ▲ 0.00% | at our read · unknown $24.43 | +10 min · unknown $24.80 ▲ 1.49% | +30 min · unknown $24.68 ▲ 1.00% | +1 hr · unknown $24.74 ▲ 1.27% | +4 hrs · unknown $25.18 ▲ 3.05% |
The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.